Andembry® Approved as a New Preventive Treatment for Hereditary Angioedema (HAE)

The approval of Andembry® as a preventive treatment for hereditary angioedema (HAE) marks an important advancement in the management of this rare genetic condition. For patients living with unpredictable and potentially life-threatening swelling attacks, this targeted therapy offers a new option for long-term disease prevention and improved quality of life.

Medical Update

• New preventive treatment approved for hereditary angioedema (HAE).
• Designed to reduce the frequency of HAE attacks.
• Targets the plasma kallikrein pathway.
• Supports long-term disease management.
• Expands treatment options for eligible patients.

What Is Hereditary Angioedema (HAE)?

Hereditary angioedema (HAE) is a rare inherited condition characterized by recurrent episodes of severe swelling affecting the skin, gastrointestinal tract, face, hands, feet, and airways. Unlike allergic angioedema, HAE attacks are not caused by histamine and therefore do not respond to antihistamines, corticosteroids, or epinephrine.

Key Characteristics

• Recurring swelling attacks without hives.
• Can affect the skin, abdomen, and upper airway.
• Often begins during childhood or adolescence.
• Usually inherited but can occur through spontaneous genetic mutations.

Understanding How HAE Develops

Most cases of hereditary angioedema are linked to problems involving the C1 esterase inhibitor (C1-INH), resulting in excessive production of bradykinin, a substance that increases blood vessel permeability and allows fluid to leak into surrounding tissues.

The Disease Pathway

• C1 esterase inhibitor deficiency or dysfunction.
• Overactivation of plasma kallikrein.
• Excess bradykinin production.
• Episodes of swelling without itching or hives.

Challenges of Living With HAE

Managing hereditary angioedema can be difficult because attacks occur unpredictably and vary greatly in severity. In some cases, swelling involving the airway can become a medical emergency requiring immediate treatment.

• Unpredictable swelling episodes.
• Risk of life-threatening airway involvement.
• Frequent emergency care or hospital visits.
• Disruption of work, school, travel, and daily activities.
• Emotional stress and reduced quality of life.

Current Treatment Approaches

Modern HAE management generally includes two treatment strategies:

• On-demand therapy to treat attacks after they begin.
• Preventive (prophylactic) therapy to reduce attack frequency over time.

While on-demand treatment remains essential, many patients with frequent or severe attacks benefit from long-term preventive therapy.

What Is Andembry®?

Andembry® is a targeted preventive therapy developed to reduce the frequency of hereditary angioedema attacks by inhibiting plasma kallikrein, a key enzyme involved in the production of bradykinin.

Unlike emergency medications used during an active attack, Andembry® is intended for ongoing disease prevention and long-term management.

How Andembry® Works

Andembry® works by inhibiting plasma kallikrein, an enzyme that plays a central role in the kallikrein-kinin system. By reducing plasma kallikrein activity, the medication decreases the production of bradykinin—the molecule responsible for the swelling attacks seen in hereditary angioedema.

How This Benefits Patients

• Reduces excessive bradykinin production.
• Helps prevent spontaneous swelling attacks.
• Targets the underlying disease mechanism.
• Supports long-term prevention rather than emergency treatment.

Clinical Studies & Regulatory Approval

The approval of Andembry® was supported by clinical studies demonstrating meaningful reductions in hereditary angioedema attack frequency while maintaining an encouraging safety profile.

Key Clinical Findings

• Significant reduction in HAE attack frequency.
• Consistent long-term preventive benefit.
• Improved patient-reported quality of life.
• Safety profile consistent with modern biologic therapies.

Safety Profile & Eligibility

Clinical studies found Andembry® to be generally well tolerated. As with any biologic therapy, treatment should be prescribed and monitored by an experienced healthcare professional.

Commonly Reported Side Effects

• Injection-site reactions.
• Mild upper respiratory symptoms.
• Headache or fatigue in some patients.

Who May Be Eligible?

• Patients with a confirmed diagnosis of hereditary angioedema.
• Individuals experiencing recurrent or severe swelling attacks.
• Patients requiring long-term preventive treatment.

Dosing & Long-Term Management

Andembry® is administered according to an approved dosing schedule designed to provide continuous suppression of plasma kallikrein activity. Following the recommended treatment schedule and attending regular follow-up appointments are important for achieving the best possible outcomes.

Improving Quality of Life

Beyond reducing swelling attacks, effective preventive treatment can significantly improve day-to-day living for people with hereditary angioedema.

• Greater confidence in daily activities.
• Reduced anxiety about unexpected attacks.
• Improved ability to travel, work, and socialize.
• Fewer emergency medical situations.
• Better overall quality of life.

Clinical Perspective

The approval of Andembry® reflects the continued shift toward targeted therapies in hereditary angioedema management. By focusing on plasma kallikrein inhibition, this treatment expands the available options for long-term disease prevention and allows specialists to further individualize care based on each patient’s clinical needs.

Key Takeaway

The approval of Andembry® represents another important advancement in hereditary angioedema care. By targeting the underlying disease pathway, this preventive therapy offers eligible patients an additional option for reducing attack frequency, improving quality of life, and supporting long-term disease management.

Find answers to common questions about Andembry® and hereditary angioedema.